APASL consensus statements and recommendation on treatment of hepatitis C.
about
On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis CEfficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseOverexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in JapanHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacistEfficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.Shortening the duration of therapy for chronic hepatitis C infection.Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.Urgency to treat patients with chronic hepatitis C in Asia.Epidemiology and treatment of hepatocellular carcinoma in Thailand.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.Impact of etiological treatment on prognosis.Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVReactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world studyIncidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.Hepatitis C virus genotypes in Myanmar.Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c.Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study.Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational studyRecovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvirSystematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
P2860
Q33803540-FB81F1D7-64F1-4064-81AF-254A6DC8076BQ36240269-0F6041B3-B346-4CC6-8992-E2D6AC2A9784Q36316437-8E805918-61D6-4EBA-A11E-AE12CE113047Q36970046-CE729E98-BF46-40F6-8068-12A07CB59645Q37578288-D011C51E-6A1F-41A0-B747-92C6CF70BA50Q37630878-B4BB2768-5193-4973-9E33-AEA9E1E8D5C7Q38375284-611327AC-F9A4-40D1-BA60-FC54C9C7566CQ38627508-2594C909-19C4-41A8-B270-69DFAF9F68E7Q38806255-046A0978-355D-4282-8AE6-E259582962FBQ39049155-2C18FD45-4770-46BF-A555-CCBAFC468DF2Q39064309-000E6239-1E74-4A6F-BFA9-37A97555E337Q39104215-42B4C643-1616-431F-A52D-F115A3B468AEQ39431994-7B56F32D-043B-4BE7-BE87-FA67A6C30ED2Q40064478-A70143A9-58DF-4A82-B4CD-3DFA4EF5A388Q40213917-5DA78846-1D99-43EE-BC1E-AC147ED56E1EQ40228687-51D2775C-216A-45C2-9E81-8BCB9EF1EFEBQ40320642-5E6228B8-52B3-4D79-962D-4F7BFC3968C1Q41108422-916FA16F-ECF8-4C88-B6CE-A50066B25D0AQ41924669-559E119C-E4B3-4604-B796-78FD2F1DAEF6Q42418913-5A45FCD2-19BC-4056-B590-9EBB95548DDFQ47121490-3A3E910B-EE37-4A82-9878-DF13335DF3F9Q47555750-BD4F8416-0B30-4035-8210-A410CF4C9C99Q47596049-5D43EA68-89AA-4886-82AF-313565CF5120Q50045992-034F80A1-8CE7-4EB2-BDAD-67EF70C3B864Q52594744-7D0F8A68-26A0-4694-B91D-BB1967B3EFB1Q53694789-527226F1-E95B-4570-805B-80FDC08127F0Q54966283-5927CE62-6845-4C55-B85F-0BE9E6503DFBQ55065074-5ADC4A24-4A8F-4761-909A-826A97B22C81Q57945693-17B90A61-9FC9-4188-8D25-C9BF719BC701Q58602166-72C7FAA9-20D1-45C8-989F-F358DB2FDD31Q58736182-F56C655E-C16C-459E-BAA5-964FABE5055C
P2860
APASL consensus statements and recommendation on treatment of hepatitis C.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
APASL consensus statements and recommendation on treatment of hepatitis C.
@en
APASL consensus statements and recommendation on treatment of hepatitis C.
@nl
type
label
APASL consensus statements and recommendation on treatment of hepatitis C.
@en
APASL consensus statements and recommendation on treatment of hepatitis C.
@nl
prefLabel
APASL consensus statements and recommendation on treatment of hepatitis C.
@en
APASL consensus statements and recommendation on treatment of hepatitis C.
@nl
P2093
P2860
P1476
APASL consensus statements and recommendation on treatment of hepatitis C
@en
P2093
A Kadir Dokmeci
Alaaeldin Ibrahim
Ankur Jindal
Barjesh Chander Sharma
Cosmas Rinaldi Adithya Lesmana
Darrell H G Crawford
Geofferey W McCaughan
George K K Lau
Jafri Wasim
Jose Sollano
P2860
P2888
P304
P356
10.1007/S12072-016-9717-6
P577
2016-04-29T00:00:00Z